157 E 32nd St. New York, NY 10016 212-689-6791

 

Welcome to the AML GOSSAMER Study

Now enrolling patients for a Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission.

MHOA Principle Investigator
Alec Goldenberg, M.D. 

For additional information contact:
Phenoia Browne, Clinical Trials Coordinator
Phone: 212-689-6791 ext 228
Email: clinicaltrials@mhony.com

AML- FLT3

Now enrolling of patients on a phase 2/3 clinical study for the treatment of AML patients with FLT3 mutations who are…

Read More

CLL

Now enrolling patients for the InformCLL Registry, which is to characterize and describe treatment patterns for those initiating treatment with…

Read More

Mantle Cell Lymphoma

Now enrolling patients in a phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of…

Read More

Hodgkin Lymphoma

The objectives of this molecular profiling protocol are to describe current treatment patterns and consequences from first-line treatment

Read More